Key statistics
As of last trade, Spyre Therapeutics Inc (3920:BER) traded at 25.95, 38.06% above the 52 week low of 18.80 set on Feb 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.75 |
---|---|
High | 25.95 |
Low | 25.75 |
Bid | 25.05 |
Offer | 26.85 |
Previous close | 25.85 |
Average volume | 0.00 |
---|---|
Shares outstanding | 51.43m |
Free float | 43.39m |
P/E (TTM) | -- |
Market cap | 1.39bn USD |
EPS (TTM) | -7.44 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 09:50 GMT.
More ▼
Press releases
- Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
- Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
- Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing
- Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
- Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics to Participate in Upcoming November Investor Conferences
- Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
- Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
- Spyre Therapeutics to Participate in Upcoming Investor Conference
More ▼